Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

Jun-ichi Nishimura, MD PhD, Kensuke Usuki, MD PhD, Julia Ramos, MD PhD, Satoshi Ichikawa, MD PhD, Jules Hernández-Sánchez, PhD, Anna Kiialainen, PhD, Alexandre Sostelly, PhD, Regis Peffault De Latour, MD PhD, Ido Paz-Priel, MD, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136048

Published: 2020

Journal Articles

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Regis Peffault De Latour, MD PhD, Simona Sica, MD PhD, Julia Ramos, MD, Jules Hernández-Sánchez, PhD, Jin Seok Kim, MD PhD, Anna Kiialainen, PhD, Sung-Soo Yoon, MD PhD, Sasha Sreckovic, MD, Antoine Soubret, PhD, Haruhiko Ninomiya, MD PhD, Alexandre Sostelly, PhD, Jens Panse, MD, Simon Buatois, PharmD, PhD, Hubert Schrezenmeier, Ido Paz-Priel, MD, Jun-ichi Nishimura, MD PhD, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-135841

Published: 2020

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Alexander Roeth, MD, Nagy Zsolt, MD PhD, Miklos Egyed, MD, Erica Winter, Joy Hsu, Andreas Dieckmann, Judith Anzures-Cabrera, Marie Mannino, Elana Fernandez, PhD, Gregor Jordan, Barbara Klughammer, PhD, Kenji Shinomiya, Naoki Kotani, Ido Paz-Priel, MD, Angelika Jahreis., MD, PhD

Blood (2017) 130 (Supplement 1): 4750.

https://doi.org/10.1182/blood.V130.Suppl_1.4750.4750

Published: 2017

Journal Articles

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

Jing Zhang, PhD, Li Li, PhD, Albert S. Baldwin, PhD, Alan D. Friedman, MD, Ido Paz-Priel, MD

Blood (2014) 124 (21): 4345.

https://doi.org/10.1182/blood.V124.21.4345.4345

Published: 2014

Journal Articles

C/EBPα or Its Leukemic Mutants Directly Activate nfkb1 Transcription and Displace HDAC1 or HDAC3 From Chromatin-Associated NF-κB p50 to Induce Anti-Apoptotic Genes.

Ido Paz-Priel, MD, Alan D. Friedman, MD

Blood (2009) 114 (22): 76.

https://doi.org/10.1182/blood.V114.22.76.76

Published: 2009

Journal Articles

C/Ebpβ Inhibits Apoptosis in Hematopoietic Cells Via Interaction with NF-κb p50.

Rebecca McFall, MD, Ido Paz-Priel, MD, Alan D. Friedman, MD

Blood (2008) 112 (11): 1332.

https://doi.org/10.1182/blood.V112.11.1332.1332

Published: 2008

Journal Articles

A Positive Feedback Loop Between C/EBPα and NF-κB p50 Inhibits Both the Intrinsic and Extrinsic Apoptosis Pathways

Ido Paz-Priel, MD, Dehua Wang, MD, Alokesh Ghosal, Ph.D., Alan D. Friedman, M.D.

Blood (2008) 112 (11): 501.

https://doi.org/10.1182/blood.V112.11.501.501

Published: 2008

Journal Articles

C/EBPα Binds and Activates the Distal PU.1 Enhancer.

Christine Yeamans, MD, Dehua Wang, MD, MS, Ido Paz-Priel, MD, Daniel G. Tenen, MD, Alan D. Friedman, MD

Blood (2006) 108 (11): 1176.

https://doi.org/10.1182/blood.V108.11.1176.1176

Published: 2006

NARROW

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

C/EBPα or Its Leukemic Mutants Directly Activate nfkb1 Transcription and Displace HDAC1 or HDAC3 From Chromatin-Associated NF-κB p50 to Induce Anti-Apoptotic Genes.

C/Ebpβ Inhibits Apoptosis in Hematopoietic Cells Via Interaction with NF-κb p50.

A Positive Feedback Loop Between C/EBPα and NF-κB p50 Inhibits Both the Intrinsic and Extrinsic Apoptosis Pathways

C/EBPα Binds and Activates the Distal PU.1 Enhancer.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only